Diabetes and metabolism Archives - Page 4 of 5

Diabetes and metabolism

Podcasts

Lifestyle modification and T2D

When it comes to lifestyle modification in the management of T2DM, dietary intervention is by far the most important

Expert/s: Dr Paul Mason

Diabetes and metabolism

Podcasts

T2D and the heart

In this era of SGLT2 inhibitors and GLP1 agonists, we need to initiate these therapies early because of their cardioprotective and renoprotective (for SGLT2I) benefits

Expert/s: A/Prof Neale Cohen

Diabetes and metabolism

Podcasts

T2D and the foot

The aim of the game in managing patients with T2DM is to keep them out of hospital; diabetic foot complications are a common and recurrent reason for patients to be admitted to hospitals

Expert/s: Prof Merlin Thomas

Diabetes and metabolism

Podcasts

What’s in and what’s out in T2D management guidelines

The evidence for the use of SGLT2 inhibitors and GLP-1a is increasing and practical tips for GPs to help us in managing patients with T2DM

Expert/s: Dr Gary Deed

Diabetes and metabolism

Podcasts

A practical approach to first, second and third line treatment

In the patient with newly diagnosed T2DM without micro or macrovascular complications, achieving good glycaemic control is important and this together with an eye to avoiding weight gain and hypoglycaemia will drive your choice of a second-line agent

Expert/s: Dr Anita Sharma

Diabetes and metabolism

Podcasts

T2D and the kidney

CKD is a marker of poor prognosis and if present, we must work hard to prevent adverse outcomes… now is the time for SGLT2i, statins, ace inhibitors, and arbs

Expert/s: Prof Merlin Thomas

Diabetes and metabolism

Podcasts

Non-insulin injectables for T2D

GLP1 agonists are a very important management option - GPs who have not yet used this class of medications should learn more and start

Expert/s: A/Prof Neale Cohen

Diabetes and metabolism

Podcasts

Indigenous diabetes

Genetic factors make lifestyle changes less effective and some are at risk of a form of malignant, rapidly progressive T2DM in the setting of severe insulin resistance

Expert/s: A/Prof Neale Cohen

Diabetes and metabolism

Monographs

SGLT2 and DPP4 Inhibition: An Ideal Combination

This article discusses the evidence for the combination use of SGLT2 inhibitors and DPP4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

Expert/s: Prof Merlin Thomas

Diabetes and metabolism

Monographs

DPP-4 Inhibitors: Similarities and Differences

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

Expert/s: Prof Merlin Thomas

Diabetes and metabolism

Monographs

Optimising Management of Type 2 Diabetes in Presence of Renal Impairment

This article discusses the medications used in type 2 diabetes and their safety in patients with renal impairment.

Expert/s: Dr Ivan Kuo

Diabetes and metabolism

Monographs

DPP-4 Inhibition: Playing the Long Game in Type 2 Diabetes

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

Expert/s: Prof Merlin Thomas

Diabetes and metabolism

Lifestyle modification and T2D

When it comes to lifestyle modification in the management of T2DM, dietary intervention is by far the most important

T2D and the heart

In this era of SGLT2 inhibitors and GLP1 agonists, we need to initiate these therapies early because of their cardioprotective and renoprotective (for SGLT2I) benefits

T2D and the foot

The aim of the game in managing patients with T2DM is to keep them out of hospital; diabetic foot complications are a common and recurrent reason for patients to be admitted to hospitals

What’s in and what’s out in T2D management guidelines

The evidence for the use of SGLT2 inhibitors and GLP-1a is increasing and practical tips for GPs to help us in managing patients with T2DM

A practical approach to first, second and third line treatment

In the patient with newly diagnosed T2DM without micro or macrovascular complications, achieving good glycaemic control is important and this together with an eye to avoiding weight gain and hypoglycaemia will drive your choice of a second-line agent

T2D and the kidney

CKD is a marker of poor prognosis and if present, we must work hard to prevent adverse outcomes… now is the time for SGLT2i, statins, ace inhibitors, and arbs

Non-insulin injectables for T2D

GLP1 agonists are a very important management option - GPs who have not yet used this class of medications should learn more and start

Indigenous diabetes

Genetic factors make lifestyle changes less effective and some are at risk of a form of malignant, rapidly progressive T2DM in the setting of severe insulin resistance

SGLT2 and DPP4 Inhibition: An Ideal Combination

This article discusses the evidence for the combination use of SGLT2 inhibitors and DPP4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

DPP-4 Inhibitors: Similarities and Differences

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

Optimising Management of Type 2 Diabetes in Presence of Renal Impairment

This article discusses the medications used in type 2 diabetes and their safety in patients with renal impairment.

DPP-4 Inhibition: Playing the Long Game in Type 2 Diabetes

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

Get the app

Site

Company

Connect

Legal

Discover

Healthed

Diabetes and metabolism

When it comes to lifestyle modification in the management of T2DM, dietary intervention is by far the most important

In this era of SGLT2 inhibitors and GLP1 agonists, we need to initiate these therapies early because of their cardioprotective and renoprotective (for SGLT2I) benefits

The aim of the game in managing patients with T2DM is to keep them out of hospital; diabetic foot complications are a common and recurrent reason for patients to be admitted to hospitals

The evidence for the use of SGLT2 inhibitors and GLP-1a is increasing and practical tips for GPs to help us in managing patients with T2DM

In the patient with newly diagnosed T2DM without micro or macrovascular complications, achieving good glycaemic control is important and this together with an eye to avoiding weight gain and hypoglycaemia will drive your choice of a second-line agent

CKD is a marker of poor prognosis and if present, we must work hard to prevent adverse outcomes… now is the time for SGLT2i, statins, ace inhibitors, and arbs

GLP1 agonists are a very important management option - GPs who have not yet used this class of medications should learn more and start

Genetic factors make lifestyle changes less effective and some are at risk of a form of malignant, rapidly progressive T2DM in the setting of severe insulin resistance

This article discusses the evidence for the combination use of SGLT2 inhibitors and DPP4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

This article discusses the medications used in type 2 diabetes and their safety in patients with renal impairment.

This article discusses the evidence for the use of DPP-4 inhibitors, in addition to standard care, in the management of type 2 diabetes.

Get the app

Site

Company

Connect

Legal

LOG IN FOR FULL ACCESS

SIGN UP FOR A FREE HEALTHED ACCOUNT

Extra Details

PASSWORD RESET

Discover

Healthed